BH vs LZB

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong recent price performance (+110.4% over 1Y), the stock trades at an extremely high P/E of 217.27 versus negative Forward P/E, signaling earnings deterioration. Profitability metrics are concerning, with a mere 0.54% net margin and 0.35% ROE, well below sector averages. While the balance sheet shows a healthy current ratio and low Price/Book of 0.50, these are overshadowed by unsustainable valuation and weak earnings momentum.

La-Z-Boy exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a conservative debt-to-equity ratio of 0.54. While the current price of $35.21 aligns closely with the Graham Number ($33.86), suggesting defensive fair value, there is a stark divergence from the growth-based intrinsic value of $14.0. The company is currently battling significant earnings contraction (-23.5% YoY) despite modest revenue growth. The outlook is a tug-of-war between a robust balance sheet and deteriorating profitability trends.